&lt;p&gt;Vitiligo and Rise in Blood Pressure – a Case–Control Study in a Referral Dermatology Clinic in Southern Iran&lt;/p&gt;

Namazi, Mohammad Reza; Rouhani, Shekoofe; Moarref, Alireza; Kiani, Mahsa; Tabei, Seyed Sajjad; Hadibarhaghtalab, Maryam

doi:10.2147/ccid.s257022

Cited by 9 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Creative Commons Attribution-Non Commercial 4.0 • September 2023 • EMJ Further, four out of the seven included studies examined the association between hypertension, a CVD-associated risk factor, and vitiligo. Namazi et al's 16 case-control study found that patients with vitiligo were diagnosed with hypertension more often than the normal population (p=0.040).…”

Section: Resultsmentioning

confidence: 99%

Assessing the Relationship Between Vitiligo and Cardiovascular Disease Risk Factors

Rahman,

Wang,

Ahmed

et al. 2023

EMJ

View full text Add to dashboard Cite

Advancements in novel combination immunotherapies as well as innovative downstream management courses offer great optimism for the applicability of emerging cancer immunotherapy to prospective treatment of cold tumours. This review comprehensively analyses and discusses notable current research directions in the field and underscores future directions for continued scientific progress alongside relevant clinical applications. Vitiligo is an autoimmune disorder characterised by white depigmented cutaneous macules. Although vitiligo may generally be considered a cosmetic disease, literature has associated broader systemic comorbidities, including a higher risk for atherosclerotic events, dyslipidaemia, and cardiovascular risk. To the authors’ knowledge, this is the first systematic review that assesses the association between vitiligo and cardiovascular disease (CVD)/CVD-associated factors. Utilising the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the authors searched PubMed and Scopus databases to identify studies available as of 30th June 2022, examining CVD and CVD-associated risk factors in patients with vitiligo. Of 2,553 articles, seven studies (four cross-sectional and three case-control), totalling 611 patients diagnosed with vitiligo (56.3% female), met the inclusion criteria for the authors’ review. Six studies suggested a significant association between patients with vitiligo and an increased risk for CVD via increased atherosclerotic events, constraint-induced movement therapy, plaque presence, dyslipidaemia, high-sensitivity C-reactive protein, oxidative stress, as well as decreased levels of vitamin D, calcium, zinc, and antioxidants. However, one study found that patients with vitiligo presented with fewer cardiovascular risk factors and increased levels of high-density lipoprotein. Although few studies indicated an increase in atherosclerotic risk due to elevated low-density lipoprotein-cholesterol and total cholesterol, contradictory high-density lipoprotein and total cholesterol levels in additional studies indicate the need for further investigation. Lastly, the association between vitiligo severity and CVD risk also indicated conflicting results. The authors’ small sample size restrained their ability to compare populations and incorporate racial and ethnic diversity to generalise their conclusions. Additional studies are required to comprehensively understand the association between vitiligo and the risk of CVD.

show abstract

Section: Resultsmentioning

confidence: 99%

Assessing the Relationship Between Vitiligo and Cardiovascular Disease Risk Factors

Rahman,

Wang,

Ahmed

et al. 2023

EMJ

View full text Add to dashboard Cite

show abstract

“…26 A high degree of co-occurrence between vitiligo and psoriasis was observed among Iranian patients. 72 Comorbidities reported in patients with vitiligo include diabetes, dyslipidaemia, obesity and hypothyroidism (Saudi Arabia) and hypertension (Iran 73 and Turkey 26 ).…”

Section: Other Comorbiditiesmentioning

confidence: 99%

Prevalence and burden of vitiligo in Africa, the Middle East and Latin America

Al Hammadi,

Silva de Castro,

Parmar

et al. 2023

Skin Health and Disease

View full text Add to dashboard Cite

Vitiligo is a common chronic autoimmune disorder characterized by skin and hair depigmentation that affects 0.5%–2.0% of the global population. Vitiligo is associated with diminished quality of life (QoL) and psychosocial burden. The burden of vitiligo may vary based on skin tone and cultural differences as well as geographical variations in disease awareness, societal stigma, healthcare systems and treatment options. Data on the burden and management of vitiligo in Africa, the Middle East and Latin America are scarce. Literature searches using terms covering vitiligo in Africa, the Middle East and Latin America were conducted using PubMed to identify relevant publications that focused on disease prevalence and burden, QoL and psychosocial impact and disease management between 2011 and 2021. Most of the reviewed studies were conducted in the Middle East, and most Latin American studies were from Brazil. Most studies involved small patient numbers and may not be generalizable. Reported prevalence of vitiligo ranged from 0.18% to 5.3% in Africa and the Middle East, and from 0.04% to 0.57% in Latin America. In several studies, prevalence was higher among female participants. Generally, non‐segmental vitiligo was the dominant clinical variant identified and the age at onset varied widely across studies. Common comorbidities include autoimmune diseases such as Hashimoto's thyroiditis, alopecia areata and diabetes. Few treatment guidelines exist in these regions, with the exceptions of guidelines published by the Brazilian and Argentinian Societies of Dermatology. There is a clear unmet need for large epidemiological studies with uniform methodology to accurately ascertain the true prevalence of vitiligo in Africa, the Middle East and Latin America. Additional data on vitiligo burden and management in Africa and Latin America are also needed, along with local disease management guidelines that consider genetic variation, psychosocial burden and socioeconomic diversity in all 3 regions.

show abstract

“…It is a well-known fact that increased catecholamine and homocysteine levels are associated with an increased risk of hypertension, a constituent of metabolic syndrome. A study by Namazi et al showed increased catecholamines in vitiligo patients compared to the control group, which they attributed to increased levels of stress in patients [ 2 ]. A study by Cucchi et al found increased levels of catecholamines and their metabolites [ 20 ].…”

Section: Reviewmentioning

confidence: 99%

“…Non-segmental vitiligo is usually bilateral and symmetrical in distribution. Segmental vitiligo is unilateral and focal in distribution [2]. The etiopathogenesis of vitiligo involves various factors, which include oxidative stress [3], autoimmune destruction of melanocytes, neural hypothesis through an accumulation of a neurochemical substance that decreases melanin production, and sympathetic nervous system activity through direct cytotoxic effect and indirectly through the generation of free radicals [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Verma¹,

Hussain²,

Namiq³

et al. 2021

Cureus

View full text Add to dashboard Cite

Vitiligo is an autoimmune condition primarily affecting the skin where there is destruction of melanocytes characterized by pinkish-white patches on the skin. It is associated with other autoimmune diseases such as thyroid disease, rheumatoid arthritis, diabetes mellitus, and metabolic syndrome. Metabolic syndrome is a constellation of disorders including insulin resistance, hypertension, dyslipidemia, and obesity, and is considered a leading cause of cardiovascular morbidity. Simvastatin is a potent hypolipidemic drug that also possesses immunomodulating properties and is a common drug used in dyslipidemia and cardiovascular diseases. This study aimed to assess the association between vitiligo and metabolic syndrome and explore the immunomodulating properties of simvastatin for use in vitiligo. We reviewed various articles from PubMed, ResearchGate, and Google Scholar using different keywords and Medical Subject Headings and finalized 33 studies to be used in our review. The articles selected showed a positive association between vitiligo and metabolic syndrome or one of the component diseases of metabolic syndrome. The benefits of using simvastatin were also addressed by few articles attributing to its antioxidant and immunomodulating effect. However, there was no concrete explanation justifying the association between vitiligo and metabolic syndrome due to a limited number of studies and smaller sample size. Large-scale clinical trials should be conducted to evaluate the use of simvastatin as an immunomodulator in vitiligo to prevent possible metabolic complications.

show abstract

<p>Vitiligo and Rise in Blood Pressure – a Case–Control Study in a Referral Dermatology Clinic in Southern Iran</p>

Cited by 9 publications

References 21 publications

Assessing the Relationship Between Vitiligo and Cardiovascular Disease Risk Factors

Assessing the Relationship Between Vitiligo and Cardiovascular Disease Risk Factors

Prevalence and burden of vitiligo in Africa, the Middle East and Latin America

Vitiligo: The Association With Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator

Contact Info

Product

Resources

About